Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02991768 · ClinicalTrials.gov registry record · Phase 2
Budesonide for Mycophenolic Acid-induced Diarrhea in Renal Transplant Recipients
A Phase 2 study, sponsored by University of Kansas Medical Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT02991768 is a Phase 2 study that was terminated before completion, run by University of Kansas Medical Center. The registered enrollment target is 9 participants.
The verdict
NCT02991768, a Phase 2 study, was terminated before completion, sponsored by University of Kansas Medical Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
The purpose of this study is to learn if using a Entocort (budesonide) to treat diarrhea will be effective and safe for kidney transplant patients, allowing them to continue with MPA medication.
Interventions
- DRUG Placebos
- DRUG Entocort
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2017-01-27 |
| Est. Completion | 2019-04-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02991768
The ClinicalTrials.gov registry entry for NCT02991768 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Kansas Medical Center, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebos is the first listed.
NCT02991768 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02991768 about?
NCT02991768 is a clinical study titled "Budesonide for Mycophenolic Acid-induced Diarrhea in Renal Transplant Recipients". The purpose of this study is to learn if using a Entocort (budesonide) to treat diarrhea will be effective and safe for kidney transplant patients, allowing them to continue with MPA medication.
What is the current status of trial NCT02991768?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2017-01-27. Estimated completion is 2019-04-26.
What interventions are being tested in trial NCT02991768?
The interventions under investigation include: Placebos (DRUG), Entocort (DRUG).
Who is sponsoring clinical trial NCT02991768?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.